 |
0 Diseases |  |
5 Trials |
|
5 Trials |  |
9 News |  |
- |||||||||| AL8326 / Advenchen
New P3 trial, Metastases: A Phase IIII Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=243, Recruiting, Sponsor: Advenchen Laboratories Nanjing Ltd.
- | AL8326 / Advenchen
Trial completion date, Trial primary completion date: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Oct 3, 2023
P2, N=36, Recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- AL8326 / Advenchen
Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ?3rd line small cell lung cancer (SCLC) treatment. (On Demand | Hall A; Poster Bd # 212) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1971;
P1/2, P2
A US Phase 2 (NCT05363280) study is ongoing and a phase 3 study is in preparation. Clinical trial information: NCT04890795.
- || AL8326 / Advenchen
Enrollment open: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Nov 3, 2022
P2, N=36, Recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
Clinical trial information: NCT04890795. Not yet recruiting --> Recruiting
- | AL8326 / Advenchen
Trial initiation date: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Oct 24, 2022
P2, N=36, Not yet recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
Not yet recruiting --> Recruiting Initiation date: Jul 2022 --> Nov 2022
- || AL8326 / Advenchen
New P1 trial: A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - Aug 3, 2022
P1, N=16, Recruiting, Sponsor: Advenchen Laboratories Nanjing Ltd.
- | AL8326 / Advenchen
New P2 trial: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - May 4, 2022
P2, N=36, Not yet recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
- | AL8326 / Advenchen
New P1/2 trial: A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - May 17, 2021
P1/2, N=237, Recruiting, Sponsor: Advenchen Laboratories Nanjing Ltd.
- | AL8326 / Advenchen
New P1 trial, Metastases: A Phase I Study of AL8326 in Advanced Solid Tumor (clinicaltrials.gov) - May 17, 2021
P1, N=40, Recruiting, Sponsor: Advenchen Laboratories Nanjing Ltd.